Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 251

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 251
---
 weighted, and then a suitable discount rate is used to arrive at the expected present value of the contingent consideration at the valuation date. The probability used in the valuation was based on published research for the probability of success of oncology companies at a similar stage of development as the Company. The discount rate was based on published rates for corporate bonds and the term was based on an estimate of the planned timing of completion of the respective development achievement that would result in payment of the respective milestones.

| Balance – June 30, 2022       |     | $(in thousands) | 163 |
|:------------------------------|:----|:----------------|----:|
| Change in fair value estimate |     |                 |   3 |
| Balance – June 30, 2023       |     |                 | 166 |
| Change in fair value estimate |     |                 |  20 |
| Balance – June 30, 2024       |     |                 | 186 |

8. Stockholders’ equity

Preferred stock

Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |        |   |     |                 |        |   |
|                                                        |     | Numberof shares          |        |   |     | $(in thousands) |        |   |
| Balance – June 30, 2022                                |     |                          | 16,838 |   |     |                 | 12,275 |   |
| Conversion of Series C Preferred stock to common stock |     |                          | (2,630 | ) |     |                 | (1,909 | ) |
| Balance – June 30, 2023                                |     |                          | 14,208 |   |     |                 | 10,366 |   |
| Conversion of Series C Preferred stock to common stock |     |                          |   (540 | ) |     |                 |   (393 | ) |
| Balance – June 30, 2024                                |     |                          | 13,668 |   |     |                 |  9,973 |   |

In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2, and C-3). Each share of Series C Preferred Stock was issued at a purchase price of $ 1,000 per share and is convertible into shares of common stock based on